<DOC>
	<DOCNO>NCT02462187</DOCNO>
	<brief_summary>This randomize , double-blind , vehicle-controlled , ascend dose study assess safety , tolerability efficacy topical nitric oxide release compound subject external genital perianal wart . Eligible subject treat topical gel ( active vehicle ) 12 week .</brief_summary>
	<brief_title>Topical NVN1000 Treatment External Genital Perianal Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>At least 2 20 genital/perianal wart maximum total wart surface area 1 % body surface area If woman childbearing potential , negative pregnancy test use effective contraception If currently receive wart treatment , willing stop treatment 28 day prior randomization study Immunocompromised patient include HIV , receive radiation , drug suppress immune system Pregnant , plan become pregnant , nursing History cancer ( include cervical cancer ) within 5 year , exception nonmelanoma skin cancer nongenital skin Recent history genital skin infection Active HSV frequent HSV recurrence unless receive suppression therapy Have hemoglobin &lt; 10 G/dl methemoglobin &gt; 3 % Known allergy component gel include excipients Previously participate study NVN1000 SB204</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>genital wart</keyword>
	<keyword>perianal wart</keyword>
</DOC>